Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Tech clinical trial

Cullinan REZILIENT3 Zipalertinib NSCLC Data Event

Analysis based on 7 articles · First reported Sep 10, 2026 · Last updated Sep 14, 2026

Sentiment
15
Attention
2
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Positive interim Phase 3 data for zipalertinib plus chemotherapy in EGFR exon 20 insertion NSCLC could support Cullinan Therapeutics pipeline value and investor confidence, potentially lifting CGEM shares. The event is company-specific and unlikely to move broader biotech or pharmaceutical indices materially.

biotechnology pharmaceuticals healthcare

Cullinan Therapeutics announced that it will host a virtual event for analysts and institutional investors on September 14, 2026, at 8:00 a.m. ET to discuss results from the planned interim analysis of the Phase 3 REZILIENT3 trial of zipalertinib plus chemotherapy in first-line EGFR exon 20 insertion mutation-positive non-small cell lung cancer (NSCLC). The interim analysis results were presented in Presidential Symposium 2 on September 13, 2026, at the International Association for the Study of Lung Cancer 2026 World Conference on Lung Cancer (WCLC), held September 12-15, 2026 in Seoul, South Korea. The trial previously met its primary endpoint of progression-free survival at the planned interim analysis. The virtual event features Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, MD, MBA, Chief Medical Officer, with a live webcast and archived replay available on the company investor relations website.

50 Cullinan Therapeutics announced virtual investor event
stock
Cullinan Therapeutics is the central company hosting the investor event and sponsor of the REZILIENT3 trial; positive data could boost its valuation and pipeline credibility.
Importance 100.0 Sentiment 30.0
per
Nadim Ahmed, Chief Executive Officer, is a featured participant in the virtual event, representing company leadership to investors.
Importance 40.0 Sentiment 10.0
per
Jeffrey Jones, Chief Medical Officer, is a featured participant in the virtual event, presenting clinical data context to investors.
Importance 40.0 Sentiment 10.0
ngo
The International Association for the Study of Lung Cancer hosts the WCLC where the REZILIENT3 interim data were presented, providing the scientific venue for the disclosure.
Importance 30.0 Sentiment 5.0
cnt
South Korea is the host country for the WCLC in Seoul, providing the location for the data presentation.
Importance 10.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.